Print

Purpose

Surfactant protein plays important role in innate immunity against respiratory viral infections. However, investigators have shown that the surfactant protein polymorphisms are associated with severity of various pulmonary diseases such as respiratory syncytial virus (RSV), tuberculosis, pediatric acute lung injury. COVID-19 virus gains entry through the respiratory system and responsible for death due to acute respiratory failure. There is a considerable heterogeneity in presentation of COVID-19 infection from asymptomatic patients to severe infection requiring intensive care and some may die. Considering reports of COVID-19 related deaths/severe disease in the same family, it is possible that genetics play an important role in severity of COVID-19 infection. Investigators propose to study the association of surfactant proteins in COVID-19 patients. Key Objectives: a) Characterize genetic markers within the surfactant protein genes in COVID-19 positive patients, b) To determine if there is a correlation between certain genetic markers and the severity of COVID-19 infection which may be used as a prognostic marker, c) To correlate genetic markers with immune studies.

Condition

Eligibility

Eligible Ages
Between 1 Day and 90 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

The major inclusion criteria is a confirmed diagnosis of COVID-19 infection performed on nasopharyngeal secretions by enzyme immunoassay or culture in patients.

Exclusion Criteria

Patients unable to sign informed consent will be excluded.

Study Design

Phase
Study Type
Observational [Patient Registry]
Observational Model
Case-Control
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Mild COVID-19 infection Patients with confirmed COVID-19 infection who remained asymptomatic and/or never hospitalized.
  • Other: Identification of genetic variants
    DNA will be extracted from whole blood from study subjects
Moderate COVID-19 infection Patients with confirmed COVID-19 infection who got admitted in general ward in the hospital.
  • Other: Identification of genetic variants
    DNA will be extracted from whole blood from study subjects
Severe COVID-19 infection Patients with confirmed COVID-19 infection who got admitted in intensive care unit and/or did not survive.
  • Other: Identification of genetic variants
    DNA will be extracted from whole blood from study subjects

Recruiting Locations

More Details

NCT ID
NCT04650191
Status
Completed
Sponsor
Milton S. Hershey Medical Center

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.